The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Nov. 28, 9:20 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #40. McKesson Corporation Celesio

Acquirer: McKesson Corporation (NYSE:MCK)
Acquiree: Celesio
Details: McKesson Corporation (NYSE:MCK), a leading North American healthcare services and information technology company, announced today that it has reached an agreement with Franz Haniel & Cie. GmbH ("Haniel") to acquire their entire holding of Celesio shares for EUR 23.50 per share. In a separate and subsequent agreement, McKesson also announced the acquisition of Celesio convertible bonds from Elliott. These agreements are not subject to any closing conditions and the transactions are expected to close within 10 business days. After the close of the agreements with Haniel and Elliott, McKesson will exceed 75% ownership of Celesio shares on a fully diluted basis.

McKesson is engaged in healthcare services. Co. operates its business in four reportable segments: U.S. Pharmaceutical, which distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; Prescription Technology Solutions, which delivers access and adherence solutions as well as dispensing support services, third-party logistics and wholesale distribution support; Medical-Surgical Solutions, which provides medical-surgical supply distribution, logistics, and other services to healthcare providers; and International, which provides distribution and services to wholesale, institutional, and retail customers.

McKesson SEC Filing Email Alerts Service


Open the MCK Page at The Online Investor »

Company Name: 
McKesson Corp
Website: 
www.mckesson.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding MCK: 
110
Total Market Value Held by ETFs: 
$7.72B
Total Market Capitalization: 
$53.99B
% of Market Cap. Held by ETFs: 
14.30%
 

Open the MCK Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree MCK Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.46 out of 4)
51st percentile
(ranked higher than approx. 51% of all stocks covered)

Analysts' Target Price:
MCK Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 40 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.